[go: up one dir, main page]

EA200000161A1 - Применение лигандов молекул мнс класса ii в качестве адъювантов для вакцинации и lag-3 в лечении злокачественных опухолей - Google Patents

Применение лигандов молекул мнс класса ii в качестве адъювантов для вакцинации и lag-3 в лечении злокачественных опухолей

Info

Publication number
EA200000161A1
EA200000161A1 EA200000161A EA200000161A EA200000161A1 EA 200000161 A1 EA200000161 A1 EA 200000161A1 EA 200000161 A EA200000161 A EA 200000161A EA 200000161 A EA200000161 A EA 200000161A EA 200000161 A1 EA200000161 A1 EA 200000161A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mhc class
lag
treatment
vaccination
adjuvants
Prior art date
Application number
EA200000161A
Other languages
English (en)
Other versions
EA003740B1 (ru
Inventor
Фредерик Триебель
Original Assignee
Энститю Гюстав Русси
Апплайд Резеч Системз Арс Холдинг Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Энститю Гюстав Русси, Апплайд Резеч Системз Арс Холдинг Н.В. filed Critical Энститю Гюстав Русси
Publication of EA200000161A1 publication Critical patent/EA200000161A1/ru
Publication of EA003740B1 publication Critical patent/EA003740B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение касается использования лиганда молекул МНС класса II, такого как CD4 и LAG-3, для производства лекарственного средства, предназначенного для профилактики или лечения патологических состояний, вовлеченных в антиген-специфичный иммунный ответ, равно как и использования LAG-3 в иммунотерапии раковых заболеваний. Также настоящее изобретение касается фармацевтической композиции, содержащей эффективное количество антигена, способного индуцировать формирование антиген-специфичного иммунного ответа наряду с эффективным количеством лиганда молекул МНС класса II, при том, что упомянутый лиганд молекул МНС класса II присутствует в качестве компонента-адъюванта.Отчет о международном поиске был опубликован 1999.07.08.
EA200000161A 1997-07-25 1998-07-23 Применение лиганда мнс класса ii, представляющего собой lag-3 или производное, мутантную форму или растворимый фрагмент lag-3, для приготовления иммунотерапевтического лекарственного средства EA003740B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97401800A EP0893507A1 (en) 1997-07-25 1997-07-25 Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
PCT/EP1998/004621 WO1999004810A2 (en) 1997-07-25 1998-07-23 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment

Publications (2)

Publication Number Publication Date
EA200000161A1 true EA200000161A1 (ru) 2000-10-30
EA003740B1 EA003740B1 (ru) 2003-08-28

Family

ID=8229825

Family Applications (3)

Application Number Title Priority Date Filing Date
EA200300092A EA200300092A1 (ru) 1997-07-25 1998-07-23 Применение лигандов молекул мнс класса ii в качестве адъювантов для вакцинации и lag-3 в лечении злокачественных опухолей
EA200200565A EA005405B1 (ru) 1997-07-25 1998-07-23 Применение опухолевых клеток, трансфицированных днк, кодирующей lag-3 или cd4, для производства лекарственного препарата для профилактики или лечения злокачественных опухолей
EA200000161A EA003740B1 (ru) 1997-07-25 1998-07-23 Применение лиганда мнс класса ii, представляющего собой lag-3 или производное, мутантную форму или растворимый фрагмент lag-3, для приготовления иммунотерапевтического лекарственного средства

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EA200300092A EA200300092A1 (ru) 1997-07-25 1998-07-23 Применение лигандов молекул мнс класса ii в качестве адъювантов для вакцинации и lag-3 в лечении злокачественных опухолей
EA200200565A EA005405B1 (ru) 1997-07-25 1998-07-23 Применение опухолевых клеток, трансфицированных днк, кодирующей lag-3 или cd4, для производства лекарственного препарата для профилактики или лечения злокачественных опухолей

Country Status (19)

Country Link
US (2) US6410509B1 (ru)
EP (3) EP0893507A1 (ru)
JP (1) JP4723722B2 (ru)
KR (1) KR100603075B1 (ru)
CN (1) CN1184320C (ru)
AT (2) ATE324455T1 (ru)
AU (1) AU753738B2 (ru)
BR (1) BR9811037A (ru)
CA (2) CA2732570C (ru)
DE (2) DE69841866D1 (ru)
DK (1) DK1002108T3 (ru)
EA (3) EA200300092A1 (ru)
EE (1) EE200000039A (ru)
ES (1) ES2262242T3 (ru)
IL (2) IL134212A0 (ru)
NO (1) NO20000378L (ru)
PT (1) PT1002108E (ru)
UA (1) UA75322C2 (ru)
WO (1) WO1999004810A2 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1295895B1 (en) * 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
AU2004217526B2 (en) 2003-02-28 2010-02-04 St. Jude Children's Research Hospital Inc. T cell regulation
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
FR2868781B1 (fr) 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP2044949A1 (en) * 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
CA2817421C (en) 2010-11-10 2020-04-14 Laboratorios Leti, S.L. Adjuvant derived from leishmania species
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN103751778B (zh) * 2014-01-28 2016-09-28 复旦大学 3′-脱氧腺苷在制备广谱疫苗增效的免疫佐剂中的应用
AU2015229103C9 (en) 2014-03-14 2020-11-26 Immutep S.A.S Antibody molecules to LAG-3 and uses thereof
EP3925968A3 (en) 2014-10-07 2022-03-02 Cytlimic Inc. Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
US9827308B2 (en) 2014-12-10 2017-11-28 Wisconsin Alumni Research Foundation Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
CN107428815B (zh) 2015-03-09 2021-07-09 Cytlimic公司 源于gpc3的肽、使用其的用于治疗或预防癌症的医药组合物、免疫诱导剂、及抗原呈递细胞的制造方法
CA2981468A1 (en) * 2015-04-07 2016-10-13 Cytlimic Inc. Medicine
IL293135A (en) 2015-05-13 2022-07-01 Agenus Inc Composition comprising at least two different complexes of a purified stress protein bound to an antigenic peptide
CN115887671A (zh) 2015-07-16 2023-04-04 百欧肯治疗有限公司 治疗癌症的组合物及方法
US10265379B2 (en) 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
EP3349790A1 (en) 2015-09-18 2018-07-25 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
US11291718B2 (en) 2016-10-11 2022-04-05 Cytlimic Inc. Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
CN108204958A (zh) * 2016-12-19 2018-06-26 伊缪泰普有限公司 结合测定
JP2021522239A (ja) 2018-04-26 2021-08-30 アジェナス インコーポレイテッド 熱ショックタンパク質結合ペプチド組成物およびその使用方法
CA3114585A1 (en) * 2018-09-27 2020-04-02 Genocea Biosciences, Inc. Treatment methods
JP2020138940A (ja) 2019-02-28 2020-09-03 テルモ株式会社 治療方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ226414A (en) * 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
JPH03505039A (ja) * 1988-08-22 1991-11-07 アメリカ合衆国 可溶性ｃｄ４を発現するレトロウイルスベクター、エイズの遺伝子治療法
JPH02231083A (ja) * 1988-08-31 1990-09-13 Eisai Co Ltd 組換ナチュラルキラー細胞活性化因子
DE69010523D1 (de) * 1989-03-03 1994-08-18 Microgenesys Inc Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.
EP0394827A1 (en) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
IL108449A (en) * 1993-01-26 2011-09-27 Weiner David B Assemblies and methods for delivery of genetic material
SE510135C2 (sv) * 1994-05-05 1999-04-19 Berol Nobel Ab Vattenhaltig suspension av en cellulosaeter, sätt för dess framställning samt komposition
DE69535375T2 (de) * 1994-05-06 2007-11-08 Applied Research Systems Ars Holding N.V. Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
CA2194488A1 (en) * 1994-08-05 1996-02-15 Tod Paul Holler Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
HUT77342A (hu) * 1994-12-07 1998-03-30 F.Hoffmann-La Roche Ag. Immunoszupresszív aktivitással rendelkező monoklonális antitest fragmensek
PL320922A1 (en) * 1994-12-23 1997-11-10 Om Lab Sa Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes
AU1355697A (en) * 1995-12-28 1997-07-28 Johns Hopkins University School Of Medicine, The Allogeneic paracrine cytokine tumor vaccines

Also Published As

Publication number Publication date
PT1002108E (pt) 2006-09-29
EP0893507A1 (en) 1999-01-27
ES2262242T3 (es) 2006-11-16
WO1999004810A2 (en) 1999-02-04
AU9254798A (en) 1999-02-16
EE200000039A (et) 2000-10-16
DE69834330T2 (de) 2007-03-29
CA2293805A1 (en) 1999-02-04
EA003740B1 (ru) 2003-08-28
CA2293805C (en) 2011-05-03
JP2001510806A (ja) 2001-08-07
WO1999004810A3 (en) 1999-07-08
US20020192195A1 (en) 2002-12-19
EP1698701A1 (en) 2006-09-06
CA2732570C (en) 2014-11-18
IL134212A0 (en) 2001-04-30
KR20010021706A (ko) 2001-03-15
JP4723722B2 (ja) 2011-07-13
CN1265149A (zh) 2000-08-30
EP1698701B1 (en) 2010-08-25
BR9811037A (pt) 2000-08-01
DK1002108T3 (da) 2006-08-21
NO20000378D0 (no) 2000-01-25
EA005405B1 (ru) 2005-02-24
US6410509B1 (en) 2002-06-25
EA200200565A1 (ru) 2002-10-31
IL134212A (en) 2012-03-29
HK1030014A1 (en) 2001-04-20
EA200300092A1 (ru) 2003-06-26
KR100603075B1 (ko) 2006-07-20
EP1002108B1 (en) 2006-04-26
DE69841866D1 (de) 2010-10-07
UA75322C2 (en) 2006-04-17
NO20000378L (no) 2000-01-25
CA2732570A1 (en) 1999-02-04
EP1002108A2 (en) 2000-05-24
US7109026B2 (en) 2006-09-19
AU753738B2 (en) 2002-10-24
CN1184320C (zh) 2005-01-12
ATE478956T1 (de) 2010-09-15
ATE324455T1 (de) 2006-05-15
DE69834330D1 (de) 2006-06-01

Similar Documents

Publication Publication Date Title
EA200000161A1 (ru) Применение лигандов молекул мнс класса ii в качестве адъювантов для вакцинации и lag-3 в лечении злокачественных опухолей
DK1468014T3 (da) Sammensætninger og fremgangsmåder til WT1-specifik immunterapi
Lewis Therapeutic cancer vaccines: using unique antigens
EA200800268A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
Lingnau et al. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines
NZ512247A (en) Compositions and methods for therapy and diagnosis of ovarian cancer
HUP0301727A2 (hu) Eljárás reumatoid artritisz kezelésére oldható mutáns CTLA4 molekula alkalmazásával
DE69839273D1 (de) Krebs immuntherapie mit semi-allogenen zellen
ES2177638T3 (es) Uso de mycobacterium para el tratamiento de tumores.
FI924222A0 (fi) Gp75 som ett tumoervaccin mot melanoma.
BR0009608A (pt) Compostos para imunoterapia e diagnóstico de câncer de mama e métodos para sua utilização
ATE239035T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendungen
NO930798L (no) Fremgangsmaate og middel mot tumorer
NO20030420D0 (no) Medikament for immunoterapi av maligne tumorer
EA200300638A1 (ru) Вакцинная композиция, содержащая трансформирующий фактор роста альфа
ATE475710T1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
EA200701071A1 (ru) Иммунотерапевтические композиции для получения аутоантител, способных предотвращать связывание интерлейкина-2 со своим рецептором и их использование в лечении рака
EP1555316A3 (en) Antigen library immunization
DK0854727T3 (da) Tumorafstødelsesantigener, der præsenteres af HLA-B44-molekyler, og anvendelser af samme
RU93004625A (ru) Способы лечения, противоопухолевые агенты
Calman et al. Immunotherapy
TH59159B (th) สารรวมที่ใช้รักษาภูมิคุ้มกันสำหรับการบำบัดรักษาเนื้องอกที่แสดงแกงกลิโอไซด์ที่มากเกินไป
TH60665A (th) สารรวมที่ใช้รักษาภูมิคุ้มกันสำหรับการบำบัดรักษาเนื้องอกที่แสดงแกงกลิโอไซด์ที่มากเกินไป

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU